Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Overview of the RATIFY study: midostaurin combination therapy for AML

In this interview, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, provides an overview of the Phase III RATIFY study (NCT00651261) of daunorubicin, cytarabine and midostaurin for the treatment of newly diagnosed acute myeloid leukemia (AML). Dr Stone highlights the implications of this regimen for the treatment of FLT3-mutated AML. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.